European Gram Negative AntiBacterial Engine


The ENABLE project was launched in February 2014 and ended in October 2021 within IMI's 'New Drugs for Bad Bugs' (ND4BB) programme. 

The ENABLE consortium worked to advance the development of promising new antibiotic compounds targeting Gram-negative bacteria such as Escherichia coli. The goal of the project was to develop attractive antimicrobial candidates for extensive preclinical studies and First-in-Human clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.

ENABLE managed a drug discovery and development engine for testing and optimising compounds in all preclinical phases of antibiotic development. ENABLE was an initiative targeted at SMEs and research institutes.

Goals of ENABLE:

    •    three antibacterial Leads
    •    two antibacterial Development Candidates
    •    at least one compound into preclinical and Phase 1 clinical studies

How did ENABLE work?

ENABLE was not only a source of funding to advance promising compounds, but it was also:

  • an expert knowledge hub

    The Portfolio Management Committee (PMC) of ENABLE was composed of 15 experts from leading EFPIA companies, universities and independent consultants from all over the globe. With their long and extensive expertise in drug discovery, clinical development and anti-bacterials they mentored scientific discovery programmes and advised on challenges as well as on how to mitigate these.

  • an alliance and collaboration to advance one common goal: fighting AMR
    Selected ENABLE participants benefitted from a well-developed drug discovery and development platform that helped advance scientific discovery programmes in a very efficient manner. ENABLE Consortium was made up of experts and staff in many fields including microbiology, chemistry, ADME, in vivo studies and safety who were providing support to bring compounds forward.

  • supportive platform for everyday challenges

    The ENABLE team and its experts were easy to approach and eager to support. The team assisted in developing detailed project plans that were in line with Big Pharma.

  • supporting raw diamonds

    If a scientific discovery programme was not yet meeting thresholds with regards to compound maturity or generated data package, ENABLE was offering a Material Transfer Agreement (MTA) Route – a kind of pre-ENABLE funding. If accepted, this was also 100% funded by ENABLE.

  • non-dilutive

    Programme owners retained full ownership of their asset and all value added through the work of ENABLE. A value sharing agreement was created within the consortium, where a small percentage of future income generated from the resulting anti-bacterial by the programme owner would be shared between partners. 

  • and of course confidential

    ENABLE had a very restrictive communication policy and only communicated what programme owners agreed upon or released themselves.


ENABLE Annual Meeting

February 12, 2018

The 5th Annual Meeting of the ENABLE consortium will take place in Riga 10-12 September 2018

ENABLE at Berlin Conference

February 28th, 2018

ENABLE was official partner of the 11th Berlin Conference on Novel Antimicrobials and AMR Diagnostics. The conference took place on the 2 March 2018 and ENABLE partners contributed to different sessions and the Marketplace.

Berlin Conference Programme

ENABLE released its fifth external newsletter

March, 2018

To read the fifth issue, click here

You can also suscribe to our Newsletter by sending an email to Dr Nathalia Murillo



April 21-24, 2018 Madrid, Spain

The world’s leading experts will join the most important congress in infectious diseases, infection control and clinical microbiology to present and discuss the latest results. More information

For more events, click here

BIO Europe Spring

May 12 - 14, 2018 Amsterdam, The Netherlands

With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a "who's who" from biotech, pharma and finance in the most innovative biopharma clusters in Europe.

More details, click here.

For more events, click here

BIO International Convention

June 4-7, 2018 Boston, US

The BIO International Convention represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
More details, here

With any queries regarding the ENABLE project, please contact the Dissemination Manager: 

Clément Robijns
Tel: 0049 (0)30-264 921-58

The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no 115583, resources of which are composed of financial contributions from the European Union`s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies` in kind contribution.